All In Biotech

Drug Trial Radar · NCT04445519

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3, Randomized, Adaptive Dose-Selection, Multi-regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 691 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

691

Actual

Start

Jun 1, 2020

Primary completion

Sep 16, 2022

Study completion Sep 16, 2022

Sponsor

Lead sponsor
Nicox Ophthalmics, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • NCX 470 0.065% (initial phase of trial)Drug

    NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)

  • Latanoprost 0.005% (initial phase of trial)Drug

    Latanoprost Ophthalmic Solution, 0.005%

  • NCX 470 0.1% (initial phase of trial)Drug

    NCX 470 Ophthalmic Solution, 0.1%

  • NCX 470 0.1% (remainder of trial)Drug

    NCX 470 Ophthalmic Solution, 0.1%

  • Latanoprost 0.005% (remainder of trial)Drug

    Latanoprost Ophthalmic Solution, 0.005%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean IOP Reduction From Time-Matched Baseline at the 8AM and 4PM Time-Points at Week 2, Week 6, and Month 3Time frame: Baseline, Week 2, Week 6, and Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.